Table 3.
Net Cost to Avoid a Major Atherosclerotic Event with Simvastatin plus Ezetimibe in SHARP
| Major Atherosclerotic Events Avoideda [A] | Simvastatin plus Ezetimibe Costsb [B] | Vascular Hospital Cost Savingsb [C] | Net Cost per Major Atherosclerotic Event Avoidedc [(B-C)/(A/1,000)] | |
|---|---|---|---|---|
| By 5-year risk of CVD | ||||
| <10% | 10 (3-18) | £1,570 (£1,531-£1,609) | £78 (£19-£151) | £157,060 (£84,090-£597,940) |
| 10%-<20% | 24 (7-43) | £1,380 (£1,342-£1,417) | £141 (£34-£261) | £50,300 (£27,130-£190,060) |
| ≥20% | 58 (17-104) | £1,137 (£1,104-£1,169) | £244 (£56-£455) | £15,230 (£7,220-£64,410) |
| By CKD stage | ||||
| 3d | 28 (3-18) | £1,454 (£1,416-£1,492) | £113 (£28-£209) | £47,280 (£26,370-£173,760) |
| 4 | 39 (11-69) | £1,449 (£1,409-£1,487) | £173 (£42-£317) | £32,020 (£17,240-£120,720) |
| 5e | 35 (9-67) | £1,182 (£1,125-£1,238) | £154 (£36-£302) | £29,210 (£14,170-£120,450) |
| On dialysis | 36 (10-65) | £1,214 (£1,175-£1,253) | £193 (£44-£369) | £28,180 (£13,820-£115,380) |
| All patients | 37 (11-65) | £1,319 (£1,298-£1,341) | £177 (£42-£326) | £30,390 (£16,050-£117,910) |
Note: Values are given as value (95% confidence interval). Simvastatin plus ezetimibe at UK £1.19 per day (2015).
Abbreviations: CKD, chronic kidney disease; CVD, cardiovascular disease; SHARP, Study of Heart and Renal Protection.
a
Per 1,000 treated for about 5 years.
b
Over about 5 years per patient.
c
With costs and events discounted at 3.5% per annum.
d
83% of participants in this category with CKD stage 3b (estimated glomerular filtration rate of 30-<45 mL/min/1.73 m2).
e
Not on dialysis therapy.